Condoliase Injection for Lumbar Disc Herniation: A New Era of Enzymatic Chemonucleolysis

Condoliase for Lumbar Disc Herniation: Evidence, Safety and the Future of Enzymatic Chemonucleolysis

By Dr Debjyoti Dutta 

This article is intended for medical education and professional discussion. It should not be interpreted as individual patient-specific medical advice or as a substitute for applicable regulatory labelling, clinical guidelines or specialist assessment.

Introduction

Lumbar disc herniation (LDH) is one of the most important causes of lumbar radicular pain, sciatica, leg pain, numbness and functional disability. While many patients improve with conservative treatment, a proportion continue to experience persistent radicular symptoms despite appropriate non-operative management. In selected patients, surgery may ultimately become necessary.

But what if there were a way to target the herniated disc itself using a minimally invasive, enzyme-based treatment?

This is where condoliase enters the field of interventional spine care.

Condoliase, also known by its development code SI-6603, is a novel chemonucleolytic agent designed to reduce the volume of the nucleus pulposus through enzymatic degradation of glycosaminoglycans within the intervertebral disc. It represents a modern evolution of the concept of chemonucleolysis, an approach that has historically included agents such as chymopapain.

Unlike an epidural intervention, which delivers treatment around the affected nerve root, condoliase is intended to act within the intervertebral disc itself.

This distinction makes condoliase particularly interesting for interventional pain physicians.

However, condoliase should not be viewed simply as a "new injection for slipped disc." The available evidence suggests that patient selection, radiological confirmation and meticulous intradiscal technique are central to its potential success.

The U.S. FDA's January 2025 advisory committee materials specifically evaluated condoliase for radicular leg pain associated with confirmed nerve-root impingement caused by lumbar disc herniation.

What Is Condoliase?

Condoliase is an enzyme with high substrate specificity for glycosaminoglycans (GAGs), including components of the nucleus pulposus. By degrading these molecules, condoliase can alter the biochemical structure of the nucleus pulposus and reduce disc volume.

The basic concept can be summarised as:

Condoliase → degradation of glycosaminoglycans → reduction in nucleus pulposus volume → reduction in intradiscal pressure → potential reduction in nerve-root compression and radicular symptoms.

The FDA presentation similarly describes condoliase as a chondroitin sulfate–degrading enzyme capable of reducing intradiscal pressure and volume.

This mechanism is fundamentally different from conventional epidural steroid treatment.

Epidural intervention

The target is primarily the epidural space and inflamed nerve root.

Condoliase

The target is the herniated intervertebral disc/nucleus pulposus itself.

Therefore, condoliase represents a disc-directed biological intervention, rather than simply another method of treating nerve-root inflammation.

Why Is Condoliase Important in Pain Medicine?

The treatment of lumbar disc herniation generally involves a spectrum of approaches:

• Education and activity modification

• Physiotherapy and rehabilitation

• Pharmacological treatment

• Epidural interventions

• Other minimally invasive spinal procedures

• Surgery in appropriately selected patients

Most patients do not require surgery. However, persistent radicular pain can have a substantial impact on mobility, sleep, work and quality of life.

The clinical challenge is particularly significant when the patient's symptoms are clearly attributable to a specific disc herniation producing nerve-root impingement, but immediate surgery is not required or the patient is seeking a less invasive treatment option.

Condoliase potentially occupies an interesting position within this treatment spectrum because it attempts to modify the disc pathology rather than merely treating the downstream inflammatory pain response.

The concept is therefore attractive:

Instead of only treating the irritated nerve root, can we reduce the offending disc material itself?

That is the fundamental therapeutic rationale behind condoliase.

Understanding the Pathophysiology

The intervertebral disc consists primarily of:

• Nucleus pulposus

• Annulus fibrosus

• Cartilaginous endplates

The nucleus pulposus is a hydrated structure rich in proteoglycans and glycosaminoglycans. These molecules contribute substantially to the disc's ability to retain water.

When disc degeneration and annular disruption occur, the nucleus pulposus may migrate through the annulus fibrosus, producing a disc protrusion, extrusion or other form of herniation.

A herniated disc can produce symptoms through two major mechanisms:

1. Mechanical nerve-root compression

The herniated disc may physically compress a spinal nerve root.

2. Chemical/inflammatory radiculopathy

Disc material can also contribute to an inflammatory response around the nerve root.

This explains an important clinical observation:

Not every MRI-visible disc herniation causes symptoms.

A patient may have a disc protrusion on MRI but no corresponding radicular symptoms.

Therefore, a disc abnormality alone should not automatically lead to an intradiscal intervention.

Clinical symptoms, neurological examination, and imaging findings must be correlated.

Why Patient Selection May Be the Most Important Issue

One of the most interesting lessons from the condoliase development program comes from the Phase 3 trials.

The FDA review evaluated three major Phase 3 studies:

• Study 1031 — positive

• Study 1131 — negative

• Study 1133 — positive

The difference between these studies provides an important lesson about patient selection.

In the FDA analysis, MRI-confirmed nerve-root impingement was present in approximately:

• 88% of patients in Study 1031

• 27% in the negative Study 1131

• 100% in Study 1133

This finding is clinically important.

The successful U.S. Phase 3 study specifically enrolled patients with demonstrable nerve-root impingement on MRI.

Therefore, one of the major lessons from the condoliase evidence is:

Condoliase is not simply a treatment for "back pain with a disc bulge." It is being studied in a much more specific clinical phenotype—radicular leg pain associated with lumbar disc herniation and confirmed nerve-root impingement.

This distinction is essential for responsible clinical application.

Condoliase Is Not a Treatment for Every Disc Herniation

A common misconception is that an MRI showing a "slipped disc" automatically makes a patient a candidate for condoliase.

That would be an oversimplification.

A clinically meaningful assessment should consider:

Symptoms

↓

Neurological examination

↓

MRI morphology

↓

Concordance between symptoms and imaging

↓

Evidence of nerve-root impingement

↓

Alternative pain generators

↓

Presence or absence of surgical indications

Only after this assessment should an intradiscal treatment be considered.

The FDA review concluded that the evidence supported treatment of radicular leg pain associated with lumbar disc herniation and confirmed nerve-root impingement, with treatment effects across the evaluated studies ranging from approximately 7.5 to 15.2 mm on the primary pain outcome.

Condoliase: From Japan to Global Clinical Research

Condoliase has been clinically developed over many years and was approved in Japan in 2018 for lumbar disc herniation associated with radicular leg pain.

Its development subsequently included randomised controlled studies designed to establish its efficacy and safety.

The Japanese Phase 3 randomised trial included patients with unilateral leg pain, a positive straight-leg-raise test and contained lumbar disc herniation. A single dose of 1.25 U was compared with placebo, with follow-up extending to one year. The trial demonstrated a statistically significant improvement in worst leg pain at Week 13.

A later U.S. Phase 3 randomised, double-blind, sham-controlled trial enrolled 352 participants and evaluated a single intradiscal injection followed by 52 weeks of observation. The primary endpoint at Week 13 showed a statistically significant advantage for condoliase over sham injection.

These trials provide the foundation for understanding where condoliase may fit within modern interventional spine practice.

A New Chapter in Chemonucleolysis

The idea behind chemonucleolysis is not new.

What is new is the possibility of applying a more targeted enzymatic approach using condoliase, combined with modern:

• MRI-based patient selection

• Image-guided procedures

• Contemporary pain assessment

• Randomised controlled trial methodology

• Long-term imaging surveillance

• Modern safety monitoring

This makes condoliase an important topic for contemporary Interventional Pain Medicine.

But enthusiasm must be accompanied by caution.

The FDA review identified important safety considerations, including disc-height loss, endplate changes, Modic changes, hypersensitivity reactions and severe cutaneous adverse reactions. Therefore, the central question is no longer simply:

"Does condoliase work?"

The more clinically relevant questions are:

Which patient should receive it?

How should the procedure be performed safely?

What are the long-term consequences for the intervertebral disc?

And where should condoliase fit within the modern treatment algorithm for lumbar radiculopathy?

These questions will determine whether condoliase becomes a niche intervention or an important component of future interventional spine care.

How Condoliase Works and What the Phase 3 Trials Really Show

How Does Condoliase Work?

The therapeutic concept behind condoliase is fundamentally different from conventional epidural treatment.

The nucleus pulposus contains a high concentration of glycosaminoglycans (GAGs), particularly chondroitin sulfate. These molecules contribute to the water-retaining properties and volume of the disc. Condoliase is a mucopolysaccharidase with high substrate specificity for these components. By enzymatically degrading GAGs within the nucleus pulposus, condoliase can alter the hydration and volume of the disc.

The proposed sequence is:

Condoliase injection

↓

Enzymatic degradation of GAGs

↓

Reduction in nucleus pulposus volume

↓

Reduction in intradiscal pressure

↓

Reduction in the mechanical component of nerve-root compression

↓

Potential improvement in radicular leg pain

The FDA presentation similarly describes condoliase as a chondroitin sulfate-degrading enzyme capable of reducing intradiscal pressure and volume.

This mechanism explains why condoliase is particularly interesting in disc-related radiculopathy, rather than nonspecific axial low back pain.

Condoliase Is Different From an Epidural Steroid Intervention

This distinction is important for pain physicians.

An epidural intervention primarily targets the epidural inflammatory environment and affected nerve root.

Condoliase is intended to act inside the affected intervertebral disc.

Therefore:

Epidural intervention	Condoliase
Primarily targets nerve-root/epidural inflammation	Targets the nucleus pulposus
Usually treats the inflammatory component	Attempts to modify the disc itself
Extra-discal	Intradiscal
Does not intentionally reduce disc volume	Designed to reduce disc volume
Commonly used for radicular pain	Investigated specifically for selected LDH-associated radicular pain

This does not mean that condoliase is superior to epidural treatment. There is no adequate head-to-head evidence establishing such superiority. Rather, the two approaches target different components of the disease process.

What Did the Phase 3 Evidence Actually Show?

The clinical development program is particularly interesting because it did not produce uniformly positive results.

Three important Phase 3 studies were evaluated:

• Study 1031 — Japan — positive

• Study 1131 — USA — negative

• Study 1133 — USA — positive

The FDA therefore did not simply look at two successful trials and declare the evidence sufficient. The agency specifically investigated why Study 1131 failed and whether the negative result could be explained by differences in patient selection and study characteristics.

That makes the condoliase story particularly valuable from an evidence-based medicine perspective.

Study 1031 — The Positive Japanese Phase 3 Trial

Study 1031 was conducted in Japan between March 2012 and February 2014.

The FDA presentation reported:

• Condoliase treatment LS mean: −49.5 mm

• Placebo LS mean: −34.3 mm

• Estimated treatment effect: −15.2 mm

• 95% CI: −24.2 to −6.2

• P = 0.0011

The primary endpoint was worst leg pain at Week 13.

This was a statistically significant result favoring condoliase.

The study therefore provided important early evidence that enzymatic chemonucleolysis could reduce radicular leg pain associated with lumbar disc herniation.

Study 1131 — The Negative U.S. Trial

The story becomes more complicated with Study 1131.

This study was conducted in the United States between September 2013 and August 2017.

Unlike Study 1031, it failed to demonstrate a statistically significant treatment benefit.

The FDA data showed:

• Condoliase LS mean: −37.7 mm

• Sham LS mean: −39.6 mm

• Estimated treatment effect: +1.9 mm

• 95% CI: −5.6 to 9.4

• P = 0.6212 

This was an important negative finding.

Rather than ignoring the result, the FDA conducted a detailed analysis to determine whether there were identifiable reasons for the failure.

Why Did Study 1131 Fail?

This may be one of the most important lessons from the entire condoliase development program.

The FDA analysis found substantial differences in the populations enrolled.

In Study 1131:

• Many patients did not have definitive MRI evidence of nerve-root impingement.

• Approximately 27% had MRI-confirmed nerve-root impingement.

In contrast:

• Study 1031: approximately 88%

• Study 1133: 100% 

This difference led to an important hypothesis:

Perhaps condoliase works best when the disc herniation is clearly responsible for nerve-root impingement and the patient's radicular symptoms.

The subsequent design of Study 1133 therefore incorporated more stringent patient-selection criteria.

The FDA presentation specifically notes that Study 1133 was modified to identify patients with demonstrable nerve-root impingement from a definitive disc herniation on MRI.

Study 1133 — The Confirmatory U.S. Phase 3 Trial

Study 1133 was designed as a:

Multicenter, randomised, double-blind, sham-controlled Phase 3 trial.

It evaluated a single intradiscal dose of 1.25 U of condoliase against a sham procedure, with follow-up for 52 weeks. The trial included patients with lumbar disc herniation and radicular leg pain.

The published study enrolled 352 participants across 41 U.S. sites.

The primary endpoint was the change in average worst leg pain at Week 13, measured using a 100-mm visual analogue scale.

The results were:

• Condoliase: −41.7 mm

• Sham: −34.2 mm

• Difference: −7.5 mm

• 95% CI: −14.1 to −0.9

• P = 0.0263 

Thus, Study 1133 met its primary efficacy endpoint.

But Is a 7.5-mm Difference Clinically Large?

This is where careful interpretation becomes important.

The result was statistically significant, but the between-group difference was approximately 7.5 mm on a 100-mm VAS.

Therefore, it is inappropriate to simply say:

“Condoliase dramatically reduces pain.”

The more accurate interpretation is:

Condoliase demonstrated a statistically significant improvement in worst leg pain compared with sham treatment at Week 13, but the magnitude of the between-group treatment effect was relatively modest.

This distinction between statistical significance and clinical significance is essential when interpreting interventional pain studies.

Interestingly, the Week-52 difference in the primary analysis favoured condoliase but did not reach statistical significance (P = 0.0558). The prespecified statistical testing sequence therefore prevented formal significance testing of some subsequent endpoints, although sensitivity analyses showed favourable findings.

Condoliase Safety: Disc-Height Loss, Endplate Changes, Hypersensitivity and SCAR

The efficacy data make condoliase an exciting development in interventional spine medicine. However, the safety profile is equally important—and arguably more important when considering a treatment that intentionally modifies the structure of the intervertebral disc.

The FDA review identified several safety signals that deserve careful consideration, particularly:

• Disc-height loss

• Endplate changes

• Modic changes

• Back pain

• Radiographic changes

• Hypersensitivity reactions

• Severe cutaneous adverse reactions (SCAR)

• The possibility of subsequent spinal surgery

The FDA presentation therefore emphasises that condoliase treatment requires appropriate patient selection, advanced anatomical knowledge, meticulous procedural skills and the ability to recognise and manage hypersensitivity and SCAR, with an appropriately staffed facility and adequate resuscitation equipment.

The Central Safety Question: What Happens to the Disc?

The mechanism of condoliase is based on enzymatic degradation of components of the nucleus pulposus.

That mechanism is therapeutically attractive because reducing disc volume may reduce the mechanical component of nerve-root compression.

But the same mechanism raises an important biological question:

Could excessive or undesirable loss of disc matrix and disc height have consequences beyond the original radicular pain?

This question became particularly important during the FDA review.

The safety analysis identified an association between condoliase treatment and disc-height loss and endplate changes.

Therefore, the treatment should not be viewed simply as:

“Inject enzyme → disc becomes smaller → pain improves.”

The intervertebral disc is a complex load-bearing structure, and changes in its height and matrix can potentially influence spinal biomechanics.

Disc-Height Loss

One of the most striking findings in the FDA safety review was the difference in disc-height loss between condoliase-treated patients and pooled sham/placebo controls.

At Week 52:

Disc-height loss

Condoliase: 15.4%

Pooled control: 6.6%

More substantial disc-height loss—defined in the FDA analysis as >30% disc-height loss—was observed in:

Condoliase: 6.2%

Pooled control: 0.3%

The differences were also apparent at earlier time points.

FDA imaging data

Time point	Disc-height loss: Condoliase	Control	>30% loss: Condoliase	Control
Week 6	10.8%	3.9%	1.3%	0%
Week 13	13.6%	3.9%	3.9%	0%
Week 26	15.8%	6.0%	6.4%	0%
Week 52	15.4%	6.6%	6.2%	0.3%

These numbers deserve attention because disc-height reduction is not simply an imaging finding. Disc height contributes to:

• Foraminal dimensions

• Segmental biomechanics

• Load distribution

• Spinal stability

• Facet joint loading

However, it is important not to automatically equate radiographic disc-height loss with clinical deterioration.

The FDA data establish an association with structural changes; they do not by themselves prove that every observed reduction in disc height will produce symptomatic degeneration or future disability.

That distinction is crucial.

Does Disc-Height Loss Mean Accelerated Degeneration?

This is one of the questions that remains incompletely answered.

The FDA presentation specifically considered:

• Disc height

• Endplate changes

• Modic changes

• Back pain

• Vertebral translation

• Vertebral posterior angle

• Long-term outcomes

The agency noted that condoliase was associated with disc-height loss and endplate changes.

But the clinical significance of these structural findings requires careful interpretation.

A reduction in disc height does not automatically mean:

“The patient will develop severe chronic back pain.”

Similarly, the presence of Modic changes does not automatically mean:

“The treatment has caused clinically significant spinal degeneration.”

Long-term clinical and imaging follow-up is therefore essential.

This is an important area for future research.

Endplate Changes and Modic Changes

The vertebral endplates form an important interface between the intervertebral disc and adjacent vertebral bodies.

Changes in the endplates can be visible on MRI and may be described using the Modic classification.

Broadly:

• Modic type 1 — associated with inflammatory/oedematous marrow changes

• Modic type 2 — associated with fatty marrow replacement

• Modic type 3 — associated with sclerosis

Modic changes have been associated with low back pain in some patients, although the relationship is complex and not deterministic.

The FDA review specifically examined the relationship between condoliase, Modic changes and back pain.

This is clinically relevant because a treatment designed to modify disc structure should ideally be evaluated not only by:

“Does the leg pain improve?”

but also:

“What happens to the disc and adjacent vertebral structures afterward?”

Progression of Disc and Endplate Changes

The FDA analysis also examined progression of imaging abnormalities over time.

In the primary safety pool, progression to certain categories of disc/endplate changes was higher in the condoliase group than in pooled controls.

For example, progression to the first category of change at Week 52 was:

31.7% with condoliase

versus

14.7% with pooled control.

Progression to the more advanced categories was much less frequent, but these findings reinforce the importance of long-term structural surveillance.

This raises an important question for future clinical studies:

Does enzymatic decompression produce a clinically meaningful trade-off between short- to medium-term radicular pain relief and longer-term structural disc changes?

At present, that question requires further investigation.

What About Spinal Instability?

The FDA review also evaluated radiographic instability.

Two parameters were specifically assessed:

Vertebral posterior angle >5°

and

Vertebral body translation >3 mm

At Week 52:

• Posterior angle >5°: 2.5% condoliase vs 2.4% control

• Vertebral translation >3 mm: 0.9% condoliase vs 0.3% control

The absolute numbers were relatively small.

Therefore, while structural changes deserve attention, the available data do not demonstrate that condoliase inevitably produces clinically significant spinal instability.

Again, radiological change and clinical consequence should not be treated as synonymous.

Spine-Related Adverse Events

The FDA presentation reported relatively few formally classified spine-related adverse events.

In the primary safety pool:

Spine-related event	Condoliase	Control
Spinal osteoarthritis	0.5%	0.3%
Retrolisthesis	0.2%	0.3%
Spondylolisthesis	0.2%	0%
Compression fracture	0%	0.5%
Foraminal stenosis	0%	0.3%
Total spinal abnormalities	0.9%	1.3%
Discitis	0.2%	0%

These event rates should be interpreted alongside the much more frequent imaging findings such as disc-height loss.

This illustrates an important point:

A radiographic change does not necessarily become a coded clinical adverse event.

What About Subsequent Lumbar Surgery?

Another clinically important question is whether patients treated with condoliase ultimately require lumbar surgery.

The FDA presentation includes long-term follow-up data from studies 10r2 and 10r3.

In Study 10r2:

Lumbar surgery rate:

• Active: 10.8%

• Placebo: 20.7%

Study 10r3 reported:

• Active: 13.5%

with follow-up extending approximately 2 to 10 years depending on the study cohort.

These findings are interesting, but they should not be interpreted as proof that condoliase prevents surgery.

The long-term cohorts were relatively small, and these data are not equivalent to a large contemporary randomised trial specifically designed to establish surgery avoidance.

Hypersensitivity: Another Important Safety Issue

Condoliase is also associated with hypersensitivity-related adverse events.

In the FDA primary safety pool:

Any hypersensitivity-related AE

Condoliase: 5.4%

Pooled placebo/sham: 4.0%

Specific events included:

• Rash: 1.9% vs 0.8%

• Urticaria: 0.5% vs 0.3%

• Asthma: 0.5% vs 0.3%

• Conjunctivitis: 0.5% vs 0%

• Contact dermatitis: 0.5% vs 0.3%

• Pruritus: 0.5% vs 0% 

Most reactions occurred relatively early after treatment.

The FDA analysis reported:

• Within 1 day: 0.5%

• Days 2–7: 2.1%

• Days 8–13 weeks: 1.9%

• ≥13 weeks: 0.9% 

This timing is important for patient counselling and post-procedure observation.

Severity of Hypersensitivity Reactions

Most hypersensitivity events were mild or moderate.

The FDA reported:

• Mild: 2.8%

• Moderate: 2.4%

• Severe: 0.2%

There were no Grade 3 or 4 hypersensitivity cases reported in the clinical trial database and no cases of anaphylaxis in the clinical trials.

However, the safety discussion does not end there.

The FDA also identified an association with severe cutaneous adverse reactions (SCAR).

Severe Cutaneous Adverse Reactions — SCAR

SCAR refers to a group of potentially life-threatening drug-related dermatological reactions.

Important examples include:

• DRESS — Drug Reaction with Eosinophilia and Systemic Symptoms

• Stevens–Johnson syndrome (SJS)

• Toxic epidermal necrolysis (TEN)

• Erythema multiforme

• Acute generalised exanthematous pustulosis (AGEP)

The FDA presentation describes these as potentially life-threatening reactions.

Importantly, the FDA presentation reports post-marketing Japanese cases in which symptoms began within the first 1–2 days after injection, with some cases requiring hospitalisation and prolonged steroid exposure.

This is a major consideration when thinking about the appropriate clinical environment for condoliase administration.

Why the Facility Matters

An intradiscal intervention involving condoliase is not simply a routine office injection.

The FDA presentation specifically highlights variability in:

• Interventional pain practice

• Staff availability

• Staff training

• Resuscitation equipment

and emphasises that treatment should be performed by appropriately qualified practitioners in a suitably equipped setting.

The FDA's final safety summary emphasises four major requirements:

1. Appropriate patient selection

2. Advanced anatomical knowledge

3. Meticulous procedural skills

4. Ability to diagnose and manage hypersensitivity and SCAR

The facility should also have:

Adequate staffing and resuscitation equipment. 

This is particularly relevant for interventional pain physicians considering the introduction of this technology into clinical practice.

The Risk–Benefit Balance

The condoliase story therefore becomes much more nuanced.

Potential benefit

Reduction of disc volume

↓

Potential reduction in nerve-root compression

↓

Improvement in radicular leg pain

Potential concern

Enzymatic modification of disc matrix

↓

Disc-height loss / endplate changes

↓

Uncertain long-term structural consequences

And alongside these structural considerations:

Hypersensitivity

• 
  

Rare but potentially serious SCAR

This is why condoliase should be approached as a specialised intervention for carefully selected patients, rather than as a routine treatment for all patients with lumbar disc disease.

What Does This Mean for the Interventional Pain Physician?

The emerging evidence suggests that successful use of condoliase will depend on much more than simply knowing how to access the disc.

The physician needs to answer three questions before considering treatment:

Question 1: Is the disc actually responsible for the patient's symptoms?

Question 2: Is there convincing evidence of nerve-root impingement?

Question 3: Can the procedure and potential adverse reactions be managed safely in the chosen clinical setting?

These questions place diagnosis and patient selection at the centre of condoliase therapy.

The technology may be innovative, but the fundamentals of interventional pain medicine remain unchanged:

The right diagnosis + the right patient + the right procedure + the right setting.

The Bigger Question

Condoliase has demonstrated efficacy in selected patients, but its safety profile introduces a fascinating clinical dilemma.

If a treatment can reduce the volume of a herniated disc and improve radicular pain, but also produces measurable changes in disc height and endplate morphology, then the long-term clinical significance of those changes becomes crucial.

This is precisely why long-term follow-up and real-world evidence will be so important.

The future of condoliase will not be determined solely by whether it can reduce leg pain at 13 weeks.

It will be determined by whether the benefit–risk balance remains favourable over years rather than months.

Who Is the Right Patient for Condoliase?

The most important lesson from the clinical development of condoliase may not be the injection itself. It is patient selection.

Condoliase is not intended simply for anyone whose MRI shows a “slipped disc.” The evidence reviewed by the FDA points toward a much more specific population: patients with lumbar disc herniation associated with radicular leg pain and demonstrable nerve-root impingement.

This distinction is critical because lumbar MRI frequently demonstrates disc abnormalities in people who have little or no corresponding clinical symptoms.

The First Principle: Treat the Patient, Not the MRI

A common problem in spine medicine is the tendency to equate an imaging abnormality with the source of pain.

A patient may have:

• Disc bulging

• Disc protrusion

• Disc extrusion

• Degenerative disc disease

• Foraminal narrowing

• Facet arthropathy

without having symptoms generated by that particular abnormality.

Therefore, before considering a disc-directed intervention, the physician must establish radioclinical concordance.

A useful clinical sequence is:

Clinical symptoms

↓

Neurological examination

↓

MRI assessment

↓

Identify the symptomatic disc

↓

Confirm nerve-root involvement

↓

Exclude competing pain generators

↓

Assess whether surgery is indicated

↓

Consider appropriate non-operative/interventional options

This approach is consistent with the important lesson emerging from the Phase 3 program.

Why the Negative Trial Matters

Study 1131 is particularly educational.

The trial did not demonstrate a significant treatment effect. The FDA subsequently investigated possible reasons for the failure.

One important difference was the proportion of patients with demonstrable nerve-root impingement.

The FDA analysis reported:

Study	MRI-confirmed nerve-root impingement
Study 1031	88%
Study 1131	27%
Study 1133	100%

The negative study also included patients in whom low back pain was greater than radicular leg pain, as well as patients with other potential pain generators.

This provides an important clinical lesson:

The more confidently the physician can establish that a specific herniated disc is producing the patient's radicular symptoms, the more closely the patient resembles the population in which condoliase demonstrated efficacy.

What Should the Clinical Assessment Include?

1. A Clear Radicular Pain Syndrome

The patient should have symptoms compatible with lumbar radiculopathy rather than isolated nonspecific axial low back pain.

The history should explore:

• Distribution of leg pain

• Dermatomal characteristics

• Pain below the knee

• Paresthesia

• Numbness

• Weakness

• Cough/sneeze-related exacerbation

• Walking and functional limitation

• Duration and progression

The clinical examination should complement the history.

2. Neurological Examination

A complete neurological assessment should include, where appropriate:

• Motor power

• Sensory examination

• Reflexes

• Straight-leg-raise testing

• Gait

• Evidence of progressive neurological deficit

The objective is not simply to document “sciatica.”

The clinician should determine whether there is a coherent neurological syndrome corresponding to the suspected nerve root.

3. MRI Confirmation

MRI is central to patient selection.

The FDA review specifically emphasised demonstrable nerve-root impingement associated with lumbar disc herniation.

The MRI assessment should therefore consider:

• Disc level

• Side

• Protrusion versus extrusion

• Relationship of the disc to the nerve root

• Foraminal involvement

• Lateral recess involvement

• Central canal involvement

• Degree of nerve-root impingement

• Other potential structural pain generators

The critical question is:

Does the MRI abnormality explain the patient's symptoms?

4. Exclude Other Major Pain Generators

Patients may have multiple abnormalities on imaging.

For example, a patient may have:

L4–L5 disc herniation

plus

L5–S1 degeneration

plus

facet arthropathy

plus

sacroiliac joint pain

plus

myofascial pain.

If the physician cannot identify the dominant pain generator, a disc-directed intervention becomes much less attractive.

This was particularly relevant to Study 1131, where patients with potential competing pain generators were included. The subsequent Study 1133 eligibility criteria were modified to reduce this diagnostic uncertainty.

5. Radicular Pain Should Be More Important Than Nonspecific Back Pain

Another important lesson from the failed Phase 3 study was the presence of patients whose low back pain exceeded their radicular leg pain.

In Study 1131, approximately 20% of patients had low back pain greater than radicular leg pain, with a higher mean baseline back-pain VAS.

Study 1133 excluded patients in whom low back pain was greater than radicular leg pain and also excluded patients with back pain attributable to other potential causes.

This is clinically significant.

Condoliase should not be conceptualised primarily as a treatment for discogenic axial low back pain.

The strongest evidence presented to the FDA relates to radicular leg pain associated with LDH and confirmed nerve-root impingement.

Who Might Be a Reasonable Candidate?

Based on the evidence discussed in the FDA review, a potentially appropriate patient profile would include:

Clinical features

• Predominantly radicular leg pain

• Symptoms consistent with a lumbar nerve-root syndrome

• Appropriate clinical-radiological correlation

• Persistent symptoms despite appropriate conservative management

Imaging features

• Lumbar disc herniation

• Concordant nerve-root impingement

• MRI findings that provide a plausible anatomical explanation for the symptoms

Clinical context

• No emergency surgical indication

• No major competing pain generator

• Appropriate procedural risk assessment

• Ability to undergo appropriate follow-up

This should be understood as an evidence-informed clinical framework, not an official FDA patient-selection algorithm.

Who Requires Particular Caution?

Condoliase deserves particular caution when:

• Symptoms are predominantly axial low back pain

• MRI findings are incidental or poorly correlated with symptoms

• Multiple potential pain generators are present

• The neurological diagnosis is uncertain

• There is significant spinal instability

• There is an active infection

• The patient has relevant hypersensitivity concerns

• The clinician cannot safely perform or monitor an intradiscal procedure

The available FDA material does not provide a universal checklist of contraindications for every clinical circumstance. Therefore, physicians should not treat this framework as a substitute for the applicable regulatory labelling, clinical-trial criteria or institutional protocols.

When Surgery Should Come First

Condoliase should never be positioned as a universal alternative to surgery.

Certain clinical situations require urgent or specialist surgical assessment.

These include situations such as:

• Cauda equina syndrome

• Progressive significant motor deficit

• Severe neurological deterioration

• Other clinically significant surgical emergencies

The fundamental principle remains:

A minimally invasive procedure should not delay necessary surgical treatment.

The role of condoliase is therefore more appropriately considered within the spectrum of treatment for carefully selected non-emergency lumbar disc herniation with radicular pain.

Where Does Condoliase Fit in the Treatment Pathway?

A practical conceptual pathway may look like this:

Lumbar radicular pain

↓

Clinical and neurological assessment

↓

MRI

↓

Concordant lumbar disc herniation + nerve-root impingement

↓

Exclude red flags and urgent surgical indications

↓

Conservative treatment where appropriate

↓

Consider appropriate interventional options

↓

Evaluate suitability for disc-directed therapy

↓

Consider condoliase in an appropriately selected patient

↓

Structured follow-up

This is a proposed evidence-informed framework, not an officially endorsed treatment algorithm.

Condoliase Versus Epidural Intervention

An important question for pain physicians is:

Should condoliase replace epidural interventions?

At present, there is no basis for making such a broad statement.

The treatments have different targets.

Epidural intervention

Primarily addresses the epidural inflammatory and nerve-root component.

Condoliase

Attempts to modify the disc itself.

Therefore, the appropriate treatment may depend on the underlying mechanism, clinical presentation and treatment objectives.

In some patients, an epidural intervention may be entirely appropriate.

In another carefully selected patient with a concordant disc herniation and nerve-root impingement, a disc-directed strategy may be considered.

The two should not automatically be viewed as competing treatments.

Condoliase Versus Surgery

Surgery provides direct mechanical removal or decompression of the offending disc material.

Condoliase takes a fundamentally different approach:

Biochemical reduction of nucleus pulposus volume rather than surgical removal of the herniated fragment.

This makes the treatment concept attractive from a minimally invasive perspective.

However, the magnitude of benefit, structural safety considerations and long-term outcomes must be considered when comparing it with established surgical approaches.

There is currently no justification for telling patients that condoliase is simply a “non-surgical replacement for discectomy.”

The Importance of Procedural Expertise

Disc access is technically more demanding than many routine interventional pain procedures.

The FDA presentation specifically notes that disc access requires detailed anatomical knowledge and involves multiple procedural variables. It also recognizes that condoliase would commonly be administered by interventional pain physicians, whose practice environments and technical approaches may vary.

Potential technical challenges include:

• Correct level identification

• Safe needle trajectory

• Avoidance of neural structures

• Avoidance of vascular structures

• Appropriate imaging

• Accurate intradiscal positioning

• Recognition of unexpected anatomy

• Management of complications

Therefore, successful implementation requires more than simply obtaining access to the disc.

The Clinical Setting Is Part of the Treatment

The FDA review highlights an important practical consideration: interventional pain procedures are performed in a variety of clinical environments, with differences in staffing, training and resuscitation capabilities.

For condoliase, this becomes particularly important because of the potential for hypersensitivity reactions and rare severe cutaneous reactions.

The FDA presentation concludes that the treatment requires:

• Appropriate prescriber expertise

• Meticulous procedural skills

• Advanced anatomical knowledge

• Ability to diagnose and manage hypersensitivity

• Ability to recognize SCAR

• Appropriate staffing

• Adequate resuscitation equipment

This reinforces an important principle:

The safety of an interventional procedure depends not only on the drug, but also on the physician, the technique and the environment in which it is performed.

The Ideal Condoliase Candidate: A Practical Summary

A useful way of thinking about the potential candidate is:

Concordant radicular symptoms

• 
  

MRI-confirmed disc herniation

• 
  

Demonstrable nerve-root impingement

• 
  

Limited competing pain generators

• 
  

No urgent surgical indication

• 
  

Appropriate procedural risk profile

=

Potential candidate for consideration of condoliase

Again, this is an evidence-informed clinical synthesis, not a substitute for regulatory labelling or patient-specific medical assessment.

What We Still Need to Learn

Despite the promising evidence, several important questions remain.

1. Which disc morphology responds best?

Is the response different in:

• Protrusion

• Extrusion

• Large extrusion

• Sequestered fragment

• Foraminal herniation

• Paracentral herniation?

2. Does symptom duration affect response?

Could outcomes differ between:

• Acute radiculopathy

• Subacute radiculopathy

• Chronic radiculopathy?

3. What happens to the disc over many years?

This is particularly important given the observed disc-height changes.

4. Can condoliase reduce the need for surgery?

The available long-term data are interesting but insufficient to answer this definitively.

5. What is the role of repeat treatment?

The FDA presentation specifically notes potential off-label practice considerations including repeat injection and treatment of multiple discs, emphasising that these areas require careful consideration.

Condoliase: A Treatment for the Right Patient, Not the Right MRI

Perhaps the most important message for clinicians is this:

The future of condoliase will depend as much on patient selection as on the pharmacology of the enzyme.

The Phase 3 program demonstrates why.

The negative Study 1131 contained a substantially lower proportion of patients with MRI-confirmed nerve-root impingement, while the subsequent positive Study 1133 enrolled patients with demonstrable nerve-root impingement.

This provides an important lesson for modern interventional pain medicine:

Do not treat the MRI. Treat the clinical syndrome that the MRI explains.

For condoliase, that distinction may be fundamental.

What Comes Next?

Condoliase has now moved the concept of chemonucleolysis into a modern era of MRI-defined patient selection, randomised controlled trials and image-guided interventional pain practice.

But the story is not finished.

The next major questions concern:

• Long-term structural outcomes

• Real-world effectiveness

• Post-marketing safety

• Patient selection

• Comparative effectiveness

• Surgery avoidance

• Appropriate procedural settings

• The potential role of Phase 4/post-marketing research

And perhaps the most important question of all:

Can we identify the precise phenotype of lumbar disc herniation in which condoliase provides the greatest benefit with the lowest long-term risk?

That is likely to be one of the defining questions for the future of enzymatic disc therapy.

The Future of Condoliase: Evidence Gaps, Phase 4 Research and Its Place in Interventional Pain Medicine

The story of condoliase (SI-6603) is not simply the story of a new drug for lumbar disc herniation. It represents a renewed attempt to use enzymatic chemonucleolysis in an era of modern MRI, image-guided intervention and increasingly precise patient selection.

The evidence reviewed by the FDA provides an important foundation: two Phase 3 studies demonstrated efficacy, while one Phase 3 study was negative; subsequent analysis highlighted the importance of MRI-confirmed nerve-root impingement and careful exclusion of competing pain generators.  

But important questions remain unanswered.

Is Condoliase Ready for Widespread Clinical Use?

The answer requires nuance.

The FDA presentation concluded that the applicant had established substantial evidence of effectiveness, with treatment effects ranging from approximately 7.5 to 15.2 mm, and that the evidence supported treatment of radicular leg pain associated with lumbar disc herniation and confirmed nerve-root impingement.

At the same time, the FDA review identified important safety considerations involving:

• Disc-height loss

• Endplate changes

• Modic changes

• Back pain

• Hypersensitivity

• SCAR

Therefore, the appropriate question is not simply:

“Does condoliase work?”

It is:

“For which patients does the benefit of condoliase outweigh its risks?”

That is a much more clinically meaningful question.

The Need for Phase 4 and Real-World Evidence

Randomised Phase 3 trials are essential for establishing efficacy and characterising common adverse events.

However, Phase 3 trials cannot answer every question.

Once a treatment enters broader clinical practice, physicians encounter:

• More diverse patient populations

• Older patients

• Different ethnic populations

• Multiple comorbidities

• Different disc morphologies

• Different procedural techniques

• Different healthcare settings

• Less restrictive eligibility criteria

This is where post-marketing surveillance and Phase 4 research, where applicable, become particularly valuable.

For condoliase, future post-marketing research should ideally investigate:

Long-term structural outcomes

What happens to disc height at:

• 1 year?

• 3 years?

• 5 years?

• 10 years?

Long-term clinical outcomes

Does early radicular pain relief translate into sustained improvement in:

• Function

• Quality of life

• Work capacity

• Physical activity?

Subsequent surgery

Does appropriately selected condoliase treatment reduce, delay or have no meaningful effect on subsequent lumbar surgery?

Rare adverse events

How frequently do uncommon hypersensitivity reactions and SCAR occur when the treatment is used in larger populations?

Phase 4 Does Not Mean “Another Phase 3”

This distinction is important for clinicians and researchers.

Phase 1

Primarily evaluates:

Safety, tolerability and pharmacological characteristics.

Phase 2

Explores:

Efficacy, dose and treatment characteristics.

Phase 3

Provides:

Confirmatory efficacy and safety evidence in larger patient populations.

Phase 4

Generally evaluates:

Post-marketing safety, effectiveness and real-world outcomes after approval.

Therefore, if condoliase enters broader clinical use, Phase 4/post-marketing evidence could be particularly valuable for answering questions that controlled Phase 3 studies cannot fully address.

An Important Research Question: Who Benefits the Most?

The Phase 3 experience strongly suggests that patient selection deserves further investigation.

The difference between the three major studies is striking:

Study 1031: 88% MRI-confirmed nerve-root impingement

Study 1131: 27%

Study 1133: 100%

This raises the possibility that future studies could identify an even more precise radiological and clinical phenotype associated with response.

Future research should examine whether treatment response varies according to:

• Disc level

• Disc morphology

• Herniation size

• Foraminal versus paracentral location

• Degree of nerve-root compression

• Acute versus chronic symptoms

• Presence of neurological deficit

• Disc degeneration

• Modic changes

• Baseline leg-pain severity

• Baseline back-pain severity

The ultimate goal would be to move from:

“Does condoliase work?”

to:

“Which exact patient is most likely to benefit?”

That would represent a major advance in precision interventional pain medicine.

Could MRI Become a Treatment-Selection Tool?

The condoliase story highlights an increasingly important concept in modern spine medicine:

Imaging is not merely diagnostic—it may eventually become predictive.

MRI already helps clinicians identify:

• Disc herniation

• Nerve-root compression

• Foraminal compromise

• Sequestration

• Endplate changes

• Disc degeneration

Future research could potentially determine whether specific MRI phenotypes predict response to condoliase.

Imagine a future algorithm:

MRI phenotype

↓

Clinical phenotype

↓

Predicted probability of response

↓

Predicted structural risk

↓

Individualised treatment decision

This would move condoliase toward a more personalised model of interventional spine treatment.

However, this remains a research concept, not an established clinical algorithm.

What About Repeat Injection?

Another important unanswered question is whether condoliase should ever be repeated.

The FDA presentation specifically identifies potential off-label practices such as:

• Repeat injection

• Treatment of multiple discs

• Non-lumbar injections

as areas of concern in interventional pain practice.

This is particularly important because the treatment itself produces structural changes within the disc.

A future research program would need to establish:

• Whether repeat treatment is effective

• Whether repeat treatment increases structural risk

• Appropriate interval between treatments

• Whether multiple-level treatment is safe

• Which patients should never undergo repeat treatment

Until robust evidence exists, these questions should not be answered through assumption or extrapolation.

Condoliase and the Future of Minimally Invasive Spine Care

The treatment of lumbar disc herniation has progressively moved toward less invasive approaches.

The therapeutic spectrum now includes:

• Conservative treatment

• Rehabilitation

• Pharmacological therapy

• Epidural interventions

• Percutaneous procedures

• Endoscopic procedures

• Surgical decompression

Condoliase introduces another concept:

Biochemical decompression of the disc.

Instead of mechanically removing the herniated disc material, the approach attempts to alter the biochemical composition of the nucleus pulposus.

This is conceptually fascinating because it sits somewhere between:

pharmacological treatment

and

interventional structural treatment.

Is Condoliase a Replacement for Surgery?

Probably the wrong question.

A better question is:

Can condoliase provide a useful treatment option for a carefully selected group of patients who do not require urgent surgical decompression?

Surgery remains essential for appropriately selected patients, particularly when there is:

• Progressive neurological deficit

• Cauda equina syndrome

• Severe neurological compromise

• Other urgent surgical pathology

Condoliase should therefore be viewed as a potential component of the treatment spectrum—not as a universal substitute for surgery.

Is Condoliase a Replacement for Epidural Steroid Interventions?

Again, not necessarily.

The two treatments have fundamentally different targets.

Epidural intervention

Targets the nerve-root/epidural inflammatory environment.

Condoliase

Targets the herniated disc/nucleus pulposus.

The future may therefore not be about one treatment replacing another.

Instead, precision medicine may allow clinicians to determine:

Which component of the patient's pain mechanism should be targeted?

For one patient, an epidural intervention may be appropriate.

For another, a disc-directed intervention may be considered.

For another, surgery may be the appropriate treatment.

Condoliase: What Should the Pain Physician Remember?

1. Condoliase is not simply another epidural intervention.

It is a disc-directed enzymatic treatment.

2. Patient selection is critical.

The strongest evidence is associated with lumbar disc herniation causing radicular leg pain with confirmed nerve-root impingement.

3. The negative Phase 3 trial is clinically important.

It demonstrates why appropriate patient selection matters.

4. The treatment effect is statistically significant but relatively modest.

The key Phase 3 treatment effects ranged from approximately 7.5 to 15.2 mm.

5. Disc-height loss requires attention.

It was more frequent with condoliase than pooled controls in the FDA analysis.

6. Structural MRI findings require long-term interpretation.

Disc-height and endplate changes do not automatically equal symptomatic deterioration.

7. Hypersensitivity is an important safety consideration.

The FDA reported hypersensitivity-related adverse events in 5.4% of condoliase-treated patients in the primary safety pool.

8. SCAR is a serious safety signal.

Although uncommon, severe cutaneous adverse reactions can be potentially life-threatening.

9. Procedural expertise matters.

The FDA emphasizes advanced anatomical knowledge, meticulous procedural technique and appropriate emergency preparedness.

10. Long-term evidence remains important.

The ultimate value of condoliase will depend on the balance between durable clinical benefit and long-term structural safety.

The Future: From Chemonucleolysis to Precision Disc Therapy

The most exciting aspect of condoliase may not be the enzyme itself.

It may be the change in thinking about disc herniation.

Historically, treatment decisions have often been based on broad clinical categories such as:

“The patient has a slipped disc.”

Modern interventional spine medicine is moving toward something much more precise:

What is the pain generator?

Which nerve root is affected?

Is the disc anatomically responsible?

What is the patient's MRI phenotype?

What intervention specifically targets that mechanism?

Condoliase fits naturally into this evolution.

It is a treatment whose potential benefit depends heavily on accurate diagnosis and precise patient selection.

Final Verdict: Is Condoliase a Paradigm Shift?

Condoliase is certainly an important development in the field of enzymatic chemonucleolysis.

The Phase 3 evidence demonstrates efficacy in appropriately selected patients, while the FDA review provides important insight into the critical role of MRI-confirmed nerve-root impingement.

However, it would be premature to describe condoliase as a universal replacement for epidural interventions, percutaneous discectomy or surgery.

The evidence instead supports a more nuanced position:

Condoliase may represent a valuable disc-directed intervention for a carefully selected subgroup of patients with lumbar disc herniation and radicular pain, particularly when clinical symptoms and MRI-confirmed nerve-root impingement are strongly concordant.

Its future clinical role will depend on answering several questions:

Who benefits most?

Who is at greatest risk?

How durable is the clinical benefit?

What are the long-term structural consequences?

Can treatment reduce the need for surgery?

How safe is the treatment in real-world practice?

And ultimately:

Can we identify the patient in whom condoliase provides the greatest reduction in radicular pain with the lowest long-term structural risk?

That is the question that future research must answer.

Conclusion

Condoliase represents a modern re-examination of an old idea—chemonucleolysis—using a more targeted enzymatic approach and contemporary clinical trial methodology.

The FDA evidence demonstrates substantial evidence of effectiveness in the appropriately selected population, while the Phase 3 experience provides an equally important lesson about the consequences of inadequate patient selection.

For interventional pain physicians, the message is clear:

Condoliase is not simply about injecting an enzyme into a disc.

It is about:

Accurate diagnosis

• 
  

Radioclinical concordance

• 
  

Appropriate patient selection

• 
  

Advanced procedural expertise

• 
  

Recognition of structural and systemic safety risks

• 
  

Long-term follow-up

The future of condoliase will therefore depend not merely on its ability to reduce disc volume, but on our ability to identify the right patient, at the right time, with the right disc pathology, in the right clinical environment.

For Asian Pain Academy, condoliase offers an important opportunity to educate the next generation of interventional pain physicians about a broader principle:

The future of interventional pain medicine is not simply more procedures—it is better patient selection, better targeting and better evidence.

About the Author

Dr Debjyoti Dutta, MD, FPM, FIPP (USA) is a Pain Physician and Interventional Pain Medicine specialist based in Kolkata. He is the Founder & Faculty of Asian Pain Academy and specialises in minimally invasive, image-guided pain interventions, spine pain, and musculoskeletal pain management.